MALE BREAST CANCER TREATMENT: CLINICAL CASE

Relevance: Male breast cancer (BC) is one of the rarest diseases and accounts for 1/100 of detected BC cases in both sexes. About 30-70% of breast cancer cases in men develop against the background of gynecomastia, particularly its nodular form. The biology of the disease differs in men, but the approaches to diagnostics and treatment are usually extrapolated from those used in women. This study aimed to demonstrate the results of each stage of a male patient with BC diagnostics and treatment. Methods: The article presents a clinical case of a male patient diagnosed with «Cancer in the right breast St III (T4NxM0), Edematous-infiltrative form with an intraductal component, upper outer localization. Immunohistochemically luminal subtype B without Her2neu expression». The data from literary sources and clinical protocols on the male BC diagnosis and treatment were also reviewed. Results: The patient received four courses of preoperative chemotherapy according to the “AС” scheme Doxorubicin 60 mg/m2 (CD 120 mg) + Cyclophosphamide 600 mg/m2 (CD 1200 mg). Intermediate instrumental and laboratory control and assessing the response to treatment according to the RECIST criteria are planned. Conclusion: The presented rare clinical case of male BC demonstrates that diagnostics and treatment at the initial stage remain the same as recommended for women. Identical preoperative and adjuvant chemotherapy regimens are applicable. Since most male BC express estrogen receptors, endocrine therapy such as tamoxifen is the kind of routine for adjuvant male BC treatment. This article describes the performed laboratory and instrumental diagnostics and preoperative chemotherapy treatment of the patient. The second part of the publication will present the results of the performed chemotherapy and surgical treatment and recommendations issued to the patient